RxDoctor Payments Data

Mark Andolina, MD

Hematology & Oncology · Cincinnati, OHNPI 1346451051

Payments from drug & device makers

$402,106in general payments, 2019–2025

Across 398 payments — averaging $1010.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$184K
  • Regeneron Healthcare Solutions, Inc.$143K
  • Merck$72K
  • Regeneron$2K
  • Pfizer$135
  • Novartis$123
  • plus $955 from 27 others

What the payments were for

  • Consulting fees$8,3582%
  • Speaking & faculty fees$349,90787%
  • Travel & lodging$34,4939%
  • Food & beverage$9,2822%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$402,106 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$104,214
Medicare patients
409
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib47$638,087
TagrissoOsimertinib Mesylate22$354,079
LenvimaLenvatinib Mesylate12$279,126
XareltoRivaroxaban229$209,523
RevlimidLenalidomide12$193,921
EliquisApixaban83$57,360
OrgovyxRelugolix13$35,886
Enoxaparin Sodium16$5,729
Sodium Chloride0.9 % Sodium Chloride24$2,515
Prochlorperazine Maleate70$1,499
Dexamethasone65$1,383
Imatinib Mesylate11$1,112
Oxycodone Hcl57$743
Megestrol Acetate22$610
Hydroxyurea33$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$89$354,07922 claims
Eisai Inc.Lenvima$24$279,12612 claims
Johnson & JohnsonXarelto$183,781$209,523229 claims
Bristol Myers SquibbRevlimid$28$193,92112 claims
PfizerEliquis$135$57,36083 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →